ONCY

Oncolytics Biotech Inc. - Form 6-K Summary

Business Context and Reporting Period

This Form 6-K, filed on November 6, 2008, reports the Third Quarter results for the period ended September 30, 2008. Oncolytics Biotech Inc. is a development-stage biopharmaceutical company focused on the clinical development of REOLYSIN, an oncolytic reovirus therapeutic for the treatment of Ras-mediated cancers. The company has not generated significant revenue and continues to incur substantial losses as it advances its clinical trial program.

Key Financial Metrics

Note: Financial data for 2007 has been restated due to the early adoption of CICA Handbook Section 3064 regarding Goodwill and Intangible Assets, which required the expensing of previously capitalized intellectual property costs.

Material Changes vs. Prior Period

• Net Loss Increase: The net loss for the nine months ended September 30, 2008, increased to $12.79 million from $11.83 million in the prior year period. This was primarily driven by higher clinical trial expenses and increased R&D salaries.
• Cash Position: Cash and cash equivalents decreased from $25.2 million at December 31, 2007, to $12.7 million at September 30, 2008, reflecting a cash usage of approximately $12.5 million from operating activities for the nine-month period.
• Expense Drivers:
  • Clinical Trial Expenses: Increased to $4.15 million (YTD 2008) from $2.98 million (YTD 2007) due to enrollment in nine active trials versus seven in the prior year and increased patient re-treatments.
  • Manufacturing Expenses: Decreased to $2.42 million (YTD 2008) from $3.55 million (YTD 2007) due to improved production yields and fewer runs required.
  • Research Collaborations: Decreased to $302,000 (YTD 2008) from $731,000 (YTD 2007) as the company reviewed and renewed only certain contracts.

Outlook, Management Commentary, and Risks

Clinical Progress and Strategy:

• Pivotal Trial Decision: In early November 2008, the Board decided to pursue a pivotal (Phase II/III) randomized trial combining REOLYSIN with paclitaxel/carboplatin for refractory head and neck cancer patients, based on compelling interim results from U.K. trials.
• Key Trial Results: Interim results presented at the iSBTc meeting showed that of 14 patients treated in U.K. trials, four had dramatic partial responses and five had stable disease. In a separate trial combining REOLYSIN with docetaxel, 9 of 11 evaluable patients experienced stable disease or better.
• New Initiatives: The company initiated a U.S. Phase II trial for non-small cell lung cancer (NSCLC) and began enrollment in an NCI-sponsored Phase II trial for metastatic melanoma.
• Manufacturing: The company completed the initial scale-up of its manufacturing process to commercial scale (100-litre facility), with the potential to produce over one million doses annually.

Financial Outlook:

• Cash Usage: Management expects average monthly cash usage for the remainder of 2008 to range between $1.4 million and $1.5 million.
• Liquidity: Existing capital resources are deemed adequate to fund operations into the second half of 2009. However, the company is evaluating financing arrangements for periods beyond that.
• Capital Markets: A base shelf prospectus was filed in June 2008 allowing for the distribution of up to $150 million in securities, though no securities have been distributed under this shelf as of September 30, 2008.

Risks and Contingencies:

• Development Stage: As a development-stage company, Oncolytics has no assurance it will ever achieve profitability or generate significant revenue.
• Capital Availability: The global financial market environment may impact the company's ability to raise additional capital through public or private offerings.
• Clinical Uncertainty: There is no guarantee that clinical trials will demonstrate safety and efficacy sufficient for regulatory approval.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $12.7 million cash balance against the projected $1.4M-$1.5M monthly burn rate to confirm funding through mid-2009.
• Accounting Restatement: Review the impact of the CICA Section 3064 adoption on historical financial comparability, specifically the reclassification of intellectual property costs from assets to expenses.
• Clinical Trial Enrollment: Monitor the enrollment rates and interim data readouts for the newly initiated U.S. NSCLC trial and the NCI melanoma trial.
• Manufacturing Scale-Up: Confirm the successful validation of the 100-litre commercial manufacturing process and the timeline for lyophilization studies.
• Capital Raising: Assess the status of the $150 million base shelf prospectus and any potential dilution from future equity offerings required to fund operations beyond 2009.